Selecting the proper treatment for cancer patients

Share:

About the research 

Immunotherapy is a very promising therapy for cancer, but only 15 to 30% of the patients respond to this kind of therapy. Giving immunotherapy to patients without knowing whether they will respond is expensive and can even harm them. That's why Madhavi Andhari (KU Leuven) is looking for markers to tell apart responders from non-responders. 🕵🏽‍♀️

Health
Cancer
Madhavi Andhari
KU Leuven

Madhavi Andhari did her masters at the Indian Institute of Science Education and Research Kolkata. In 2020, she finished her master's thesis in mechanogenomics at the National University of Singapore. She is currently working on characterizing the immune microenvironment of melanoma patients at the KU Leuven Cancer Institute. 

Gerelateerde video's